Bristol-Myers Squibb Co. (BMY) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where th...
Bristol-Myers Squibb Co.'s revenue decreased 0.2% year over year, from $48.30B to $48.19B.
Net income increased 178.8% over the same period, from $-8.95B to $7.05B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 148% in total.
Total debt decreased by 9.1% to $45.11B.
The debt-to-equity ratio stands at 2.44, indicating a high leverage profile.
Operating cash flow declined 6.8% to $14.16B.
Bristol-Myers Squibb Co. maintains a healthy net profit margin of 14.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $33.53B+48.6% | $6.26B | $25.58B | $6.77B | $9.61B | $91.26B | $37.60B | $29.00B |
| Q1 FY2024 | $11.87B-64.6% | $-11.91B | $8.93B | $-11.52B | $2.83B | $99.03B | $55.68B | $16.49B |
| Q2 FY2024 | $24.07B+102.8% | $-10.23B | $17.87B | $7.98B | $5.16B | $94.65B | $52.39B | $17.02B |
| Q3 FY2024 | $35.96B+49.4% | $-9.02B | $26.80B | $12.56B | $10.75B | $93.67B | $49.75B | $17.14B |
| Q1 FY2025 | $11.20B-68.8% | $2.46B | $8.17B | $2.97B | $1.95B | $92.43B | $49.71B | $17.39B |
| Q2 FY2025 | $23.47B+109.5% | $3.77B | $17.07B | $4.74B | $5.87B | $94.68B | $49.19B | $17.43B |
| Q3 FY2025 | $35.69B+52.1% | $5.97B | $25.85B | $7.86B | $12.18B | $96.89B | $48.98B | $18.55B |
| Q1 FY2026 | $11.49B-67.8% | $2.68B | $8.07B | $3.24B | $1.10B | $86.48B | $44.46B | $20.07B |
Balance Sheet Summary (Latest Period)
Total Assets
$90.04B
Total Liabilities
$71.53B
Total Equity
$18.47B
Cash & Equivalents
$10.67B
Total Debt
$45.11B
Current Assets
$29.39B
Current Liabilities
$23.42B
Retained Earnings
$16.90B